An open label, randomized, parallel, phase II trial to evaluate the efficacy and safety of cremophor-free, polymeric micelle formulation of paclitaxel compared to paclitaxel in subjects with ovarian cancer.

被引：0
|
作者：
Kim, Yong-Man
Lee, Shin-Wha
Cho, Chi Heum
Hur, Soo-Young
Kim, Byoung-Gie
Kim, Jae Hoon
Kim, Seung Cheol
Kim, Seok-Mo
Kim, Young-Tae
Ryu, Hee Sug
Kang, Soon-Beom
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[2] Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Seoul, South Korea
[6] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[7] Chonnam Natl Univ, Sch Med, Dept Obstet & Gynecol, Kwangju, South Korea
[8] Yonsei Univ, Severance Hosp, Dept Obstet & Gynecol, Seoul 120749, South Korea
[9] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 441749, South Korea
[10] Konkuk Univ, Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5568
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
    Rob, Lukas
    Cibula, David
    Knapp, Pawel
    Mallmann, Peter
    Klat, Jaroslav
    Minar, Lubos
    Bartos, Pavel
    Chovanec, Josef
    Valha, Petr
    Pluta, Marek
    Novotny, Zdenek
    Spacek, Jiri
    Melichar, Bohuslav
    Kieszko, Dariusz
    Fucikova, Jitka
    Hrnciarova, Tereza
    Korolkiewicz, Roman Pawel
    Hraska, Marek
    Bartunkova, Jirina
    Spisek, Radek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [42] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] An open-label phase 1 trial of the safety and efficacy of daily subcutaneous SPL-108 injections when used in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.
    Girda, Eugenia
    de Meritens, Alexandre Buckley
    Finlayson, Malcolm
    Leiser, Aliza
    Nelson, David
    Silverman, Michael H.
    Stephenson, Ruth
    Rodriguez-Rodriguez, Lorna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies
    Akerley, W. L.
    Schabel, M.
    Morrell, G.
    Horvath, E.
    Yu, M.
    Johnsson, B.
    Arbogast, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A phase IB/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer.
    Del Priore, Giuseppe
    Hoffman, Steve
    Nixon, Daniel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial.
    Huang, Weiwei
    Chen, Qi
    Shen, Yangkun
    Wang, Chenxi
    Huang, Zhijian
    Liu, Jian
    Wang, Lili
    Wu, Fan
    Chen, Xinhua
    Li, Nani
    Hong, Yi
    Chen, Mulan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up
    Ghebeh, Hazem
    Al-Sayed, Adher
    Suleman, Kauser
    Eiada, Riham Eiada
    Tulbah, Asma
    Al-Tweigeri, Taher
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
  • [48] MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial-A randomized phase II study of carboplatin and paclitaxel plus /- cetuximab, in advanced and/or recurrent cervical cancer.
    Pignata, Sandro
    Scambia, Giovanni
    Lorusso, Domenica
    De Giorgi, Ugo
    Nicoletto, Maria Ornella
    Lauria, Rossella
    Mosconi, Anna Maria
    Sacco, Cosimo
    Omarini, Claudia
    Tagliaferri, Pierosandro
    Ferrandina, Gabriella
    Cinieri, Saverio
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Salutari, Vanda
    Piccirillo, Maria Carmela
    Daniele, Gennaro
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
    Shi, M.
    Gu, A.
    Tu, H.
    Huang, C.
    Wang, H.
    Yu, Z.
    Wang, X.
    Cao, L.
    Shu, Y.
    Yang, R.
    Li, X.
    Chang, J.
    Hu, Y.
    Shen, P.
    Guo, Z.
    Tao, M.
    Zhang, Y.
    Liu, X.
    Sun, Q.
    Zhang, X.
    Jiang, Z.
    Zhao, J.
    Chen, F.
    Yu, H.
    Zhang, W.
    Sun, J.
    Li, D.
    Zhou, J.
    Han, B.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 85 - 96
  • [50] A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)
    Hidalgo, M.
    Pazo-Cid, R.
    Guillen-Ponce, C.
    Lopez, R.
    Vera, R.
    Reboredo, M.
    Munoz, A.
    Martinez de Castro, E.
    Diaz Beveridge, R.
    La Casta, A.
    Martin-Valades, J. I.
    Cubillo, A.
    Martinez-Galan, J.
    Ales, I.
    Sastre, J.
    Macarulla Mercade, T.
    ANNALS OF ONCOLOGY, 2017, 28
12345